What's coming to Contemporary OBGYN® this week?
Alabama’s attorney general retracted comments he made last week suggesting criminal prosecution for women taking abortion pills for pregnancy termination. He is now saying that only providers who prescribe the pills could be prosecuted.
If approved, DARE-HRT1 would become the first FDA-approved monthly intravaginal ring to deliver both estrogen and progestin hormone therapy.
In this month's Legally Speaking column, Hindi Stohl, MD, JD, and James M. Shwayder, MD, JD, dissect a case of shoulder and abdominal dystocia during a vaginal delivery for fetal hydrops.
Findings from a study in JAMA Network Open reveal valuable insight into the way cannabis legalization has impacted the perceptions of pregnant women who use cannabis in the US.
Results of a study in JAMA Network Open sought to answer the question: Is proton pump inhibitor use during pregnancy associated with an increased risk of congenital malformations?
Many couples experiencing infertility are hesitant to get vaccined for COVID-19, resulting from misinformation on social media. A research letter in JAMA Network Open investigates the impact of COVID-19 vaccinations on artificial insemination-by-partner outcomes.
Check back soon for additional updates!
Adverse maternal outcomes after uterine conservation in placenta accreta spectrum
May 9th 2024A review of 5 studies reveals a significant 1 in 4 incidence of adverse maternal outcomes following uterine conservation in patients with placenta accreta spectrum, underlining the importance of expert multidisciplinary care.
Read More
Barriers in seeking pelvic floor disorder treatment among ethnic minorities
May 8th 2024A recent shed light on how ethnic minority groups perceive pelvic floor disorders, highlighting barriers to treatment seeking and the importance of raising awareness about available treatment options.
Read More
Variations found in testosterone therapy for women with HSDD
May 7th 2024Dive into the intricate landscape of testosterone therapy prescriptions among women with hypoactive sexual desire disorder, revealing diverse patterns in duration, administration routes, and estrogen co-administration.
Read More